Pfizer Inc. has recalled approximately 544,400 packages of Duavee (conjugated estrogens/bazedoxifene) 0.45/20 mg tablets because the medication failed dissolution specifications. This defect means the tablets may not break down or dissolve as intended after being swallowed. The recall affects 30-count packages (two 15-tablet blister cards) that were distributed nationwide. Consumers are advised to consult with their healthcare provider regarding their treatment and return affected products for a refund.
If the medication fails to dissolve properly, the body may not absorb the correct amount of active ingredients. This can lead to a lower-than-intended dose, which may reduce the effectiveness of the drug in managing symptoms or preventing the conditions for which it was prescribed.
Contact your healthcare provider or pharmacist for guidance. Return any unused product to the pharmacy for a refund
AI-Enhanced Content: The summary, action steps, and risk assessment on this page were generated by AI from official government recall data to improve readability. This is not legal or medical advice. Always refer to the official agency sources below for authoritative information.
Sources: FDA iRES · Raw API Response
openFDA Disclaimer: This recall information is sourced from the openFDA API. Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Refer to the openFDA terms of service for more information.